Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

Acne Vulgaris Clinical Trial

Official title:

Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo's Adapalene/BP Gel to Galderma's Epiduo (Adapalene/BP) Gel, and Both Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03393494
• Other study ID #: PRG-NY-17-008
• Status: Completed
• Phase: Phase 3
• Start date: December 13, 2017
• Est. completion date: January 5, 2019

Study information

• Verified date: November 2021
• Source: Padagis LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of Acne Vulgaris

Recruitment information / eligibility

• Status: Completed
• Enrollment: 825
• Est. completion date: January 5, 2019
• Est. primary completion date: September 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Signed IRB approved written informed consent/assent

2. 12 to 40 years of age, inclusive.

3. Clinical diagnosis of facial acne vulgaris with an inflammatory lesion (papules and pustules) count of 20-50, inclusive and a non-inflammatory (open and closed comedones) lesion count of 25-100 inclusive and no more than 2 nodulocystic lesions (e.g., nodules and cysts) including those present on the nose.

4. Baseline Investigator's Global Assessment Score of 3 (moderate) or 4 (severe) on a severity scale of 0 to 4.

5. Females of child bearing potential (excluding women who are surgically sterilized (tubal ligation or bilateral oophorectomy or hysterectomy) or post-menopausal for at least 2 years), in addition to having a negative urine pregnancy test at Visit 1/Day1(Baseline), must be willing to use an acceptable form of birth control during the study.

Exclusion Criteria:

1. Pregnant, breastfeeding or planning a pregnancy within the period of their study participation period.

2. Presence of more than 2 facial Nodulocystic lesions.

3. Presence of any other facial skin condition that, in the Investigator's opinion, might interfere with acne vulgaris diagnosis and/or evaluations

4. Any uncontrolled, chronic or serious disease or medical condition that would prevent participation in a clinical trial, or, in judgment of the investigator, would put the subject at undue risk or might confound the study assessments

5. Excessive facial hair that would interfere with the diagnosis or assessment of acne vulgaris.

6. History of unresponsiveness to topical adapalene and/or benzoyl peroxide therapy.

7. Currently using any product containing adapalene and/or benzoyl peroxide and/or belonging to the same family.

8. History of hypersensitivity or allergy to adapalene, benzoyl peroxide, retinoids and/or any ingredient in the study medication.

9. Use of medications known to exacerbate acne

10. Start or change within 3 months (90 days) of Visit 1 and throughout the study

11. Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days (1 month) of study entry and throughout the study

12. Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.

13. Subjects who in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study.

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Drug:
• Adapalene and Benzoyl Peroxide Topical Gel
Test product
• Epiduo Topical Product
RLD product
• Placebo
Placebo gel

Locations

Country	Name	City	State
United States	Dermatology Consultants	High Point	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Padagis LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Percent Change From Baseline in the Papules and Pustules Lesion Count		Day 1 to week 12
Primary	Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count	Per protocol population	Day 1 to week 12